title: Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
abstract: 5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells. Half-life (t1/2) values for the elimination of DFUR and 5-fluorouracil (5-FU) from plasma following DFUR (100 mg/kg) administration were about 0.80 and 0.39 hr, respectively. Plasma 5-FU AUC (area under the curve) values following oral DFUR (100 mg/kg) was 0.224 micrograms.hr/ml. If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t1/2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 micrograms.hr/ml, respectively. Thus, BVDU significantly increased the plasma levels of 5-FU. It had no effect on the plasma levels of DFUR. At 100 mg/kg, DFUR did not show a significant antitumor activity. At 500 mg/kg it effected a 90% inhibition in tumor growth. When combined with BVDU (10 mg/kg), DFUR at 100, 200 and 300 mg/kg reduced tumor growth by 96, 100 and 100%, respectively. The antitumor activity achieved by DFUR, in the presence or absence of BVDU, correlated highly significantly with the AUC values for plasma 5-FU.
authors.affiliation: Chemotherapy Division, National Cancer Center Research Institute, Tokyo.
authors.forename: M
authors.initials: M
authors.lastname: Iigo
authors.forename: K
authors.initials: K
authors.lastname: Nishikata
authors.forename: Y
authors.initials: Y
authors.lastname: Nakajima
authors.forename: A
authors.initials: A
authors.lastname: Hoshi
authors.forename: N
authors.initials: N
authors.lastname: Okudaira
authors.forename: H
authors.initials: H
authors.lastname: Odagiri
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004357:Drug Synergism; D005467:Floxuridine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005472:Fluorouracil / Q000097:blood*; D006207:Half-Life; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D013056:Spectrophotometry, Ultraviolet
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; C020235:brivudine; D001973:Bromodeoxyuridine; D005472:Fluorouracil; C025034:doxifluridine